JP2020530989A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530989A5
JP2020530989A5 JP2020503988A JP2020503988A JP2020530989A5 JP 2020530989 A5 JP2020530989 A5 JP 2020530989A5 JP 2020503988 A JP2020503988 A JP 2020503988A JP 2020503988 A JP2020503988 A JP 2020503988A JP 2020530989 A5 JP2020530989 A5 JP 2020530989A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
cell
car
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020503988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/043779 external-priority patent/WO2019023396A1/en
Publication of JP2020530989A publication Critical patent/JP2020530989A/ja
Publication of JP2020530989A5 publication Critical patent/JP2020530989A5/ja
Priority to JP2023117421A priority Critical patent/JP2023134735A/ja
Withdrawn legal-status Critical Current

Links

JP2020503988A 2017-07-25 2018-07-25 強化されたキメラ抗原受容体およびその使用 Withdrawn JP2020530989A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023117421A JP2023134735A (ja) 2017-07-25 2023-07-19 強化されたキメラ抗原受容体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762536934P 2017-07-25 2017-07-25
US62/536,934 2017-07-25
PCT/US2018/043779 WO2019023396A1 (en) 2017-07-25 2018-07-25 ENHANCED CHIMERIC ANTIGENIC RECEPTORS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023117421A Division JP2023134735A (ja) 2017-07-25 2023-07-19 強化されたキメラ抗原受容体およびその使用

Publications (2)

Publication Number Publication Date
JP2020530989A JP2020530989A (ja) 2020-11-05
JP2020530989A5 true JP2020530989A5 (https=) 2021-09-02

Family

ID=65040821

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020503988A Withdrawn JP2020530989A (ja) 2017-07-25 2018-07-25 強化されたキメラ抗原受容体およびその使用
JP2023117421A Pending JP2023134735A (ja) 2017-07-25 2023-07-19 強化されたキメラ抗原受容体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023117421A Pending JP2023134735A (ja) 2017-07-25 2023-07-19 強化されたキメラ抗原受容体およびその使用

Country Status (9)

Country Link
US (1) US20240336699A1 (https=)
EP (2) EP4582146A3 (https=)
JP (2) JP2020530989A (https=)
KR (1) KR20200032174A (https=)
CN (2) CN111432823A (https=)
AU (1) AU2018306307B2 (https=)
CA (1) CA3070998A1 (https=)
TW (1) TW201908335A (https=)
WO (1) WO2019023396A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3883955A1 (en) * 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
EP4018198A1 (en) 2019-08-21 2022-06-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for detecting, quantifying and monitoring immune-cell mediated cytotoxicity of cell populations comprising immune cells and/or stem cells
NL2023924B1 (nl) * 2019-10-01 2021-06-01 Lely Patent Nv Meetsysteem voor levensmiddelen
CN115461361B (zh) * 2020-05-08 2025-03-14 玛希敦大学 嵌合抗原受体和携带该受体的经修饰的细胞
KR102297396B1 (ko) * 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
CN116981685A (zh) * 2020-12-03 2023-10-31 世纪治疗股份有限公司 基因工程化细胞及其用途
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CN113045658B (zh) 2020-12-11 2021-12-24 广州百暨基因科技有限公司 抗cll1抗体及其应用
WO2022174172A1 (en) * 2021-02-15 2022-08-18 H. Lee Moffitt Cancer Center And Research Institute Inc. Customized chimeric antigen receptor polypeptides
WO2022216624A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
JP2024514522A (ja) 2021-04-07 2024-04-02 センチュリー セラピューティクス,インコーポレイテッド 遺伝子導入ベクターおよび細胞を操作する方法
BR112023018844A2 (pt) 2021-04-07 2023-10-10 Century Therapeutics Inc Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
CA3216557A1 (en) * 2021-04-14 2022-10-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors to target cd5-positive cancers
WO2023069936A1 (en) * 2021-10-18 2023-04-27 Kite Pharma, Inc. Signaling domains for chimeric antigen receptors
AU2022423987A1 (en) 2021-12-29 2024-07-11 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CN119698467A (zh) 2022-06-08 2025-03-25 世纪治疗股份有限公司 衍生自遗传工程化以具有膜结合的il12的诱导多能干细胞的免疫效应细胞及其用途
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
AU2023375625A1 (en) 2022-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
EP4720302A1 (en) * 2023-05-25 2026-04-08 Legend Biotech Ireland Limited Chimeric antigen receptors and uses thereof
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
TR201904484T4 (tr) * 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
BR112014029417B1 (pt) * 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
JP6647868B2 (ja) * 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗EGFRvIIIキメラ抗原受容体を用いたがんの処置
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3925618A1 (en) * 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
CA2945388A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
US20170333480A1 (en) * 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
US10786549B2 (en) * 2015-04-23 2020-09-29 Baylor College Of Medicine CD5 chimeric antigen receptor for adoptive T cell therapy
EP4212547A1 (en) * 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
WO2017112877A1 (en) * 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Chimeric antigen receptors and enhancement of anti-tumor activity

Similar Documents

Publication Publication Date Title
JP2020530989A5 (https=)
JP7599205B2 (ja) 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
CN112638947B (zh) 用于治疗实体瘤的嵌合抗原受体细胞
US20200038443A1 (en) Multi-function and multi-targeting car system and methods for use thereof
JP2022548778A5 (https=)
JP2024500847A5 (https=)
EP4400516A1 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CN118546959A (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CA3090546A1 (en) Chimeric antigen receptors targeting the tumor microenvironment
JP2020517259A5 (https=)
CN108138148B (zh) T细胞的激活和扩增
JP2015527070A5 (https=)
WO2014165818A2 (en) Compositions and methods for preventing and treating prostate cancer
WO2018045034A1 (en) Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
JP2021530971A (ja) 様々な構築物最適化を備えたt細胞抗原カプラ
JP2023515055A5 (https=)
AU2025204510A9 (en) Car library and scFv manufacturing method
AU2021267893A1 (en) Anti-tumor associated antigen antibodies and uses thereof
WO2025093035A1 (en) Cd40-targetting antibodies and uses thereof
WO2023177974A2 (en) Anti-mesothelin antibodies and uses thereof
US20250136703A1 (en) Anti-il13ra2 antibodies and uses thereof
JP2025538424A (ja) 併用療法の投与レジメン
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof
WO2024210072A1 (ja) キメラタンパク質、核酸、ベクター、t細胞又はnk細胞、医薬組成物、組み合わせ物、組み合わせ医薬、及び標的抗原結合タンパク質
EP4615501A1 (en) Anti-5t4 antibodies and uses thereof